Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Major Depressive Disorder (MDD)
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: SSRI (escitalopram or sertraline) — 11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
  • Drug: Extended-Release Memantine — 6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
  • Drug: Placebo — 6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment

Primary Outcomes

  • Pattern Separation Performance (At baseline (week 0) and after completing the medication trial (week 11))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jeffrey Miller
Principal Investigators:
  • Jeffrey M Miller, MD (PRINCIPAL_INVESTIGATOR) - New York State Psychiatric Institute (NYSPI)
Contact Information
Study Contact:
Jeffrey Miller, MD
646-774-7613
HDRFstudy@nyspi.columbia.edu
Abigail Byrnes
HDRFstudy@nyspi.columbia.edu
Jeffrey M Miller, MD
646-774-7613
HDRFstudy@nyspi.columbia.edu
New York State Psychiatric Institute (NYSPI)
Interventions
  • Drug: SSRI (escitalopram or sertraline) — 11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
  • Drug: Extended-Release Memantine — 6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
  • Drug: Placebo — 6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment
Study Locations (1 sites)
New York State Psychiatric Institute (NYSPI), New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-50 * Current diagnosis of MDD without psychotic features assessed within three weeks of study enrollment * 17-item Hamilton Depression Rating Scale score ≥17 assessed within 3 weeks of study enrollment * Using an effective form of contraception at study enrollment and agrees to continue throughout study participation for individuals of child-bearing potential * Capacity to provide informed consent * Proficient in English * Willing to provide emergency contact Exclusion Criteria: * Currently taking an antidepressant medication at study enrollment * Pregnant or breastfeeding at time of enrollment * Evidence of current unstable medical illness, including liver or renal impairment, or unstable cardiovascular or respiratory illness * QTc interval greater than 500 ms * Current genitourinary conditions that raise urine pH such as a) renal tubular acidosis or b) severe infection of the urinary tract. * Clinically significant neurological conditions, including a) history of stroke, b) previous head injury with evidence of cognitive impairment, c) history of malignancy or d) history of seizure disorder. (headache, migraines, pain disorders, and other conditions not exclusionary) * Lifetime diagnosis of a) bipolar disorder, b) psychotic disorder, or c) dementia * Current active suicidal ideation * Current substance use disorder other than tobacco use disorder * Current or recent (past 6 months) treatment with antipsychotics; current or recent (past 1 month) treatment with benzodiazepines; current use of prescribed stimulant medication; current use of other NMDA antagonists (amantadine, ketamine, dextromethorphan) * Current use of disulfiram with oral concentrate, MAOIs (including linezolid or IV methylene blue), or pimozide * History of hypersensitivity or allergic reaction to a) memantine hydrochloride or any of its components/excipients, b) citalopram, escitalopram, or any other component of the product, or c) sertraline or any other component of the product * Concurrent or recent (past 6 months) participation in another clinical trial for mental illness involving an investigational product or device * Lack of response to or intolerable side-effects from trials of two or more selective serotonin reuptake inhibitors of adequate dose and duration at study enrollment * Electroconvulsive therapy (ECT) in the past 6 months * Any condition or material in the body that is a contraindication for MRI procedures * Weight that exceeds 300 lbs or inability to fit into MRI scanner * MST LDI score greater than 0.5
Conditions Type 2 Diabetes Mellitus (T2DM), Food Ef...
Phase PHASE2
Enrollment 68
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts. The main parameters it aims to answers are : 1. Does food effects the pharmacokinetic parameters following a single dose of MKP10241 in healthy participants? 2. Will multiple ascending doses of MKP10241 in obese participants with or without T2DM characterize changes in the plasma pharmacokinetic profile and pharmacodynamic effects? 3. What treatment emergent adverse events or discontinuation is experienced following single and multiple ascending doses of MKP10241 in healthy and obese participants with or without T2DM? This study will be compared against a placebo which is matched in appearance to MKP10241 at dosage strengths. Participants will: 1. Part 1: Take MKP10241 400 mg or Placebo on Day 1 and Day 8. Part 2: Take MKP10241 200 mg, 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 Part 3: Take MKP10241 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 2. Visit the clinical research unit for dose administration, admission or follow up. 3. Will be monitored by the Safety Monitoring Committee.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MKP10241 — Oral liquid suspension of unit dose strength 6.6 mg/mL
  • Drug: Placebo — Oral liquid suspension matched in appearance to MKP10241 at dosage strengths

Primary Outcomes

  • Part 1 - Food effect of single dose of MKP10241 on Maximum concentration of drug (Cmax) (18 days)
  • Part 1 - Food effect of single dose of MKP10241 on Apparent total clearance of drug (CL/F) (18 days)
  • Part 1 - Food effect of single dose of MKP10241 on Time to maximum concentration (Tmax) (18 days)
  • Part 1 - Food effect of single dose of MKP10241 on elimination half life (t1/2 ) (18 days)
  • Part 1 - Food effect of single dose of MKP10241 on lag time (Tlag) (18 days)
  • Part 1 - Food effect of single dose of MKP10241 on Apparent Volume of distribution of drug (V/F) (18 days)
  • Part 1 - Food effect of single dose of MKP10241 on Area under the curve from time 0 to 24hrs - AUC (0-24h) (18 days)
  • Part 1 - Food effect of single dose of MKP10241 on AUC(0-last) (18 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-12
Completion: 2026-04-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mankind Pharma Limited
Collaborators: Emerald Clinical Inc.
Principal Investigators:
  • Stephen Hall, MBBS, FRACP (PRINCIPAL_INVESTIGATOR) - Veritus Research
Contact Information
Study Contact:
Mohammad M Ahsan, B. Pharm, M.Sc
+91 124 2873900
muneeb.ahsan@mankindpharma.com
Santosh Kumar Rai, MSc, PhD
+91 124 2873900
santosh.rai@mankindpharma.com
Stephen Hall, MBBS,MD
03 8736 1758 Or 0494 062 402
info@veritusresearch.com
Veritus Research
Interventions
  • Drug: MKP10241 — Oral liquid suspension of unit dose strength 6.6 mg/mL
  • Drug: Placebo — Oral liquid suspension matched in appearance to MKP10241 at dosage strengths
Study Locations (1 sites)
Veritus Research, Bayswater, Victoria 3153 Australia
Eligibility Criteria
Inclusion criteria * Male or female participants between 18 to 60 years of age * Considered healthy by the Investigator. Part 1: BMI of 18 to 30 kg/m2, and weight being not less than 50 kg. Part 2/3: BMI of ≥32 kg/m2 * Part 1/2: Fasting plasma glucose (FPG) between 3.9 mmol/L and 6.1 mmol/L. Part 3: FPG greater than or equal to 6.94 mmol/L and less than or equal to 14.43 mmol/L * A nonsmoker/social smoker, defined as not having smoked more than 5 cigarettes or equivalent per day in the 3 months prior to Screening. * Able to abstain from the consumption of alcohol and any alcohol-containing products from 48 hours before dosing to the End of Study Visit. * Female participants must be of nonchildbearing potential or, if of childbearing potential, must agree to use 1 form of highly effective contraceptive method, plus an additional barrier method of contraception between signing consent * Male participants who are sexually active must use a condom from Screening until at least 90 days after the last dose of study intervention (or be surgically sterile. Female partners of childbearing potential must use a highly effective method of contraception. * Capable of giving signed Informed Consent * Willing and able to adhere to study restrictions and to be confined at the CRU. * Part 3: Participants with an established diagnosis of type 2 diabetes mellitus * Part 3: Participants; type 2 diabetes mellitus must be managed by diet and exercise alone or by stable dose of metformin (for ≥2 months); the use of other antidiabetic therapies is prohibited Exclusion criteria * Clinically significant haematological findings at Screening. * Hepatic impairment including aspartate aminotransferase (AST), alanine transaminase (ALT), or alkaline phosphatase ≥1.5 times upper limit of normal (ULN), total bilirubin ≥2.0 times ULN, albumin ≤3.0 g/L, serum amylase or lipase ≥1.5 times ULN at Screening. * Renal impairment, such as creatinine ≥ULN, estimated glomerular filtration rate (eGFR) of ≤80 mL/minute/1.73m2 in adults, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula * Positive polymerase chain reaction (PCR) test for severe-acute-respiratory-syndrome-related coronavirus (SARS-CoV-2) * A history of non-febrile seizures. * Positive pregnancy test result at Screening or on admission to the CRU, * Any major surgery within 60 days prior to Screening, or planned major surgery during the study. * Any history of malignant disease excluding surgically resected skin and in-situ cervical squamous cell or basal cell carcinoma. * Suspected hypersensitivity to MKP10241 and any components of MKP10241 liquid suspension * Any other condition which makes the participant unsuitable for study participation as judged by the Investigator or designee. * Participant has any history or evidence of any clinically significant disease * Prior or planned (during study period) bariatric surgery (e.g. gastric bands, gastroplasty Roux-e-Y gastric bypass) or ileal resection. * Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-V) substance use disorders and alcohol abuse within 12 months prior to Screening and/or positive alcohol breath test at Screening or admission. * Positive result for drugs of abuse at Screening or admission. * Use of live attenuated vaccines within 14 days prior to dosing * The use of medications (other than paracetamol), including hormonal contraceptives * Receipt of any other investigational medicinal product within one month or five half-lives (whichever is longer) prior to dosing. * Clinically significant ECG findings: QTcF value ≥450 ms for males or ≥470 ms for females at Screening or Day -1 * Participants with a mean systolic blood pressure \>140 mmHg, mean diastolic blood pressure \>90 mmHg at Screening. * Positive blood screen for human immunodeficiency virus antibody (HIV), hepatitis B surface antigen (HBsAg), syphilis, hepatitis C virus (HCV). * Change in body weight of ≥ 10% within 3 months prior to the Screening visit. * Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products, plasma) or acute loss of blood during the 30 days prior to Screening. * Part 3: Type 1 diabetes mellitus, maturity-onset diabetes of the young, or other forms of diabetes.
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 800
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Agreement between AI tool results and genetic test results (Through study completion, an average at one year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-20
Completion: 2026-08-11
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (3 sites)
Research Site, Golania, Goiás 74605-020 Brazil
Research Site, Porto Alegre, Rio Grande do Sul 90035-001 Brazil
Research Site, Porto Alegre, Rio Grande do Sul 90035-903 Brazil
Eligibility Criteria
Inclusion Criteria: * female patients, * aged 18 years or older, * identified as high genetic risk by breast surgeons, * referred to a geneticist, and * who agree to participate in the study. Exclusion Criteria: * male patients, * absence of complete information in the medical records, * patients unaware of their biological family history, and * patients who do not agree to participate in the study.
Conditions Chronic Insomnia
Phase NA
Enrollment 76
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomized-controlled trial that assesses the efficacy of a brief Acceptance and Commitment Therapy (ACT-i), compared to an attentional control group, in adults with chronic insomnia. The interventions will be evaluated for their impact on insomnia severity, cognitive function, depression, anxiety, psychological flexibility, and sleep beliefs - measured before treatment, two weeks after and at a three-month follow-up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Acceptance and Commitment Therapy for Insomnia — Monotherapy ACT-i, with no behavioral components, is a brief and low-intensity treatment that has recently been detailed by experts in the field in a session-by-session guideline, intending to help people affected by chronic insomnia. The key components of the sessions are psychoeducation, mindfulness, values and actions derived from chosen values, and defusion. An adapted, brief and online version of the intervention was developed by the authors of this study. Both interventions were matched in terms of overall duration and delivery format. Each session was tailored to follow a comparable format. Therapeutic alliance, psychoeducation, sleep hygiene, relaxation training and homework was targeted in the first session. In the second session, ACT-i focused on values, acceptance strategies and psychological flexibility. This version will be published online upon request. Each session will last 120 min. They will be delivered once per week, for two consecutive weeks.
  • Behavioral: Attentional Control Group — The focus of the sessions will be on participants, on general topics. It will not include any active, psychological intervention components, such as cognitive restructuring or ACT processes. No recommendations or psychological guidance will be given. Each session will last 120 minutes. It will be held once per week, for two weeks.

Primary Outcomes

  • Change in the score of Insomnia Severity Index (ISI); (baseline, 2 weeks after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-23
Completion: 2026-10-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Babes-Bolyai University
Contact Information
Study Contact:
Roxana Cardoș, PhD
+40 751 477 323
roxanaoltean@psychology.ro
Babes Bolyai University
Larisa C.I. Tînc, PhD Student
077459079
larisa.tinc@ubbcluj.ro
Babes Bolyai University
Interventions
  • Behavioral: Acceptance and Commitment Therapy for Insomnia — Monotherapy ACT-i, with no behavioral components, is a brief and low-intensity treatment that has recently been detailed by experts in the field in a session-by-session guideline, intending to help people affected by chronic insomnia. The key components of the sessions are psychoeducation, mindfulness, values and actions derived from chosen values, and defusion. An adapted, brief and online version of the intervention was developed by the authors of this study. Both interventions were matched in terms of overall duration and delivery format. Each session was tailored to follow a comparable format. Therapeutic alliance, psychoeducation, sleep hygiene, relaxation training and homework was targeted in the first session. In the second session, ACT-i focused on values, acceptance strategies and psychological flexibility. This version will be published online upon request. Each session will last 120 min. They will be delivered once per week, for two consecutive weeks.
  • Behavioral: Attentional Control Group — The focus of the sessions will be on participants, on general topics. It will not include any active, psychological intervention components, such as cognitive restructuring or ACT processes. No recommendations or psychological guidance will be given. Each session will last 120 minutes. It will be held once per week, for two weeks.
Study Locations (1 sites)
Babes Bolyai University, Cluj-Napoca, Romania
Eligibility Criteria
Inclusion Criteria: * clinical/ subclinical diagnosis of chronic insomnia either already diagnosed by a professional, or identified with SCISD-R by our team of clinicians * age over 18 and older, but not over 59 years old; * minimal/ mild symptomatology of depression (scores ≤ 9 on PHQ-9) and/ or anxiety (scores ≤ 9 on GAD-7) or as diagnosed with SCID-5-CV; Exclusion Criteria: * diagnosed with a neurological degenerative disorder, or any moderate/ severe psychiatric disorder; * diagnosed with other sleep disorder (e.g., sleep apnea, restless legs/ periodic limb movements, circadian-based sleep disorder); * diagnosed with cognitive impairments; * unable to understand Romanian; * unable to attend to online-sessions (e.g., no laptop, microphone, camera);
Conditions Type 2 Diabetes Mellitus (T2DM), Chronic...
Phase PHASE4
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The global prevalence of diabetes is increasing substantially. Around 40 % of patients with type 2 diabetes develop chronic kidney disease. Diabetic kidney disease is the leading cause of kidney failure, it is closely linked to cardiovascular disease and heart failure and is associated with a threefold increase in all-cause mortality and a 16-year loss in life expectancy. In large clinical trials, the novel drug finerenone has shown to lower the risk of chronic kidney disease progression and improve the cardiovascular outcome for patients with type 2 diabetes and chronic kidney disease. However these trials did not not reflect current standard-of-care for patients with type 2 diabetes and chronic kidney disease, as only a minority (6.7 %) received an SGLT2-I - a treatment that has been considered standard-of-care for these patients since 2022. The FineCaRe study aims to investigate the effect of treatment with finerenone in combination with an SGLT2-I on albuminuria and left ventricular mass in patients with type 2 diabetes and chronic kidney disease. The investigators will perform a 26-week investigator-initiated, single-center, placebo-controlled, double-blinded randomized clinical trial. After screening and inclusion, participants will be randomized 1:1 to either finerenone or placebo treatment. Outcomes will be assessed at baseline, during and after 26 weeks of treatment. The primary goal of the FineCaRe study is to acquire new knowledge that may help in preventing kidney failure in diabetic patients. With this project the investigators aim to contribute to the understanding of which disease mechanisms in the kidneys and heart that can be targeted in diabetic patients with kidney disease. This could hopefully provide better opportunities for preventing chronic kidney disease and kidney failure.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Finerenone (BAY 94-8862) — Patients with an eGFR of 25-60 ml/min/1.73m2 will receive an initial dose of 10 mg finerenone/placebo once daily and those with an eGFR of at least 60 ml/ in/1.73m2 will receive an initial dose of 20 mg finerenone/placebo once daily. From 4 weeks the target dose is 20 mg finerenone/placebo once daily. An increase in dose from 10 to 20 mg once daily will be encouraged after 4 weeks provided the plasma potassium level is 4.8 mmol/L or less and the eGFR stable. If eGFR is reduced with \>30 % compared to the previous measurement, we will not increase the dose of finerenone/placebo. Plasma potassium and eGFR will be measured 4 weeks after any initiation, re-start or increase in dose. A decrease in dose from 20 to 10 mg is allowed at any time after initiation of finerenone or placebo. Patients in the placebo group will undergo sham adjustment of the dose. Finerenone or placebo will be withheld if potassium concentrations exceed 5.5 mmol/L and restarted if potassium levels fall to 5.0 mmol/L
  • Drug: Placebo — Placebo tablets matching BAY94-8862 are administered orally.

Primary Outcomes

  • Change in left ventricular mass measured by non-contrast cardiac MRI of the heart (From the baseline visit at week 0 to the end of treatment at week 26.)
  • Change in albuminuria measured by a urinary albumin-to-creatinine ratio (UACR) in morning spot urine samples (first morning voids). (From the baseline visit at week 0 to the end of treatment at week 26.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-10-23
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Collaborators: Aarhus University Hospital
Contact Information
Study Contact:
Lene Halkjær, MD
+4528928399
lene.halkjaer@clin.au.dk
Per L Poulsen, Professor
perpouls@rm.dk
Lene Halkjær, MD
+4528928399
lene.halkjaer@clin.au.dk
Steno Diabetes Center Aarhus
Interventions
  • Drug: Finerenone (BAY 94-8862) — Patients with an eGFR of 25-60 ml/min/1.73m2 will receive an initial dose of 10 mg finerenone/placebo once daily and those with an eGFR of at least 60 ml/ in/1.73m2 will receive an initial dose of 20 mg finerenone/placebo once daily. From 4 weeks the target dose is 20 mg finerenone/placebo once daily. An increase in dose from 10 to 20 mg once daily will be encouraged after 4 weeks provided the plasma potassium level is 4.8 mmol/L or less and the eGFR stable. If eGFR is reduced with \>30 % compared to the previous measurement, we will not increase the dose of finerenone/placebo. Plasma potassium and eGFR will be measured 4 weeks after any initiation, re-start or increase in dose. A decrease in dose from 20 to 10 mg is allowed at any time after initiation of finerenone or placebo. Patients in the placebo group will undergo sham adjustment of the dose. Finerenone or placebo will be withheld if potassium concentrations exceed 5.5 mmol/L and restarted if potassium levels fall to 5.0 mmol/L
  • Drug: Placebo — Placebo tablets matching BAY94-8862 are administered orally.
Study Locations (1 sites)
Steno Diabetes Center Aarhus, Aarhus N, 8200 Denmark
Eligibility Criteria
Inclusion Criteria: * Age above 18 years. * Diagnosis of type 2 diabetes according to the World Health Organization definition. * Current treatment with a SGLT2-I1 at maximally tolerated dose. * Current treatment with an ACE inhibitor or an ARB1 at maximally tolerated dose. * Plasma potassium level of 4.8 mmol/L or less at the time of screening. * CKD defined as eGFR ≥25 ml/min/1.73 m2 and albuminuria (UACR between 30-5000 mg/g). * Speak and understand Danish fluently. Exclusion Criteria: * Inability to give informed consent. * Severe renal disease with eGFR \<25 ml/min/1.73m2. * Severe hepatic disease (plasma ALAT above 3 x upper limit of normal). * Active cancer diagnosis other than basal cell carcinoma. * Treatment with systemic steroids at time of randomization. * Bariatric surgery within 2 years or other gastrointestinal surgeries that induce chronic malabsorption. * Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake. * Chronic or acute pancreatitis. * Pregnancy or breastfeeding (see pregnancy below). * Poorly controlled medical condition, e.g. congestive heart failure (New York Heart Association III-IV or EF ≤ 40%), recent (within 3 months) stroke or acute myocardial infarction or any other condition that in the opinion of the investigator will put the trial participant at risk if participating in the trial. * Allergy to finerenone or any of the excipients contained in the drug. * Current systemic treatment with strong inhibitors of CYP3A4 (e.g. itraconazol, ketoconazole, ritonavir, cobicistat, clarithromycin) or strong inducers of CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital). * Current treatment with other MRAs (e.g. spironolactone, eplerenone etc.). * Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose- galactose malabsorption. * Addison's disease. * Contraindications to MRI. * Previous renal or heart transplantation.
Conditions Hypertension, Eating Behaviors
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out how early time-restricted eating affects body rhythms and improves cardiometabolic health in older adults.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Early time-restricted eating — The participants will be asked to fast for a target of 16 hours per day (eat ad libitum within the 8-hour eating window, starting between 6:30-8:30 am), 6 days/week for 12 weeks. Participants will be allowed to consume calorie-free beverages, sugar-free gum, and will be encouraged to drink plenty of water throughout the entire intervention period.

Primary Outcomes

  • Blood glucose (Baseline and 12 weeks)
  • Heart rate variability (Baseline and 12 weeks)
  • Systolic Blood pressure (Baseline and 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-16
Completion: 2028-07-31
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: UAB Nutrition Obesity Research Center
Contact Information
Study Contact:
Yi Lin, PhD
205-996-5876
yilin@uabmc.edu
University of Alabama at Birmingham
Yi Lin, PhD
University of Alabama at Birmingham
Interventions
  • Behavioral: Early time-restricted eating — The participants will be asked to fast for a target of 16 hours per day (eat ad libitum within the 8-hour eating window, starting between 6:30-8:30 am), 6 days/week for 12 weeks. Participants will be allowed to consume calorie-free beverages, sugar-free gum, and will be encouraged to drink plenty of water throughout the entire intervention period.
Study Locations (1 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Eligibility Criteria
Inclusion Criteria: * Consent to participate in the study * Men and women ≥ 60 years old * Average office systolic BP ≥130 mmHg * Self-reported ≥12 hours eating period per day of at least 5 days/week * Stable health history over the past 2 months Exclusion Criteria: * Fasting \>12 hours per day * Actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake * Have lost ≥ 10 pounds in last 3 months * Unable to wake up at a regular time between 6-8 am * Perform overnight shift work more than 1day/week on average * Resting heart rate of \>120 beats per minute, systolic blood pressure \> 180 mmHg and/or diastolic blood pressure of \> 100 mmHg * Have been diagnosed with diabetes * On insulin or diabetes medication * Unstable angina, heart attack or stroke in the past 3 months * Continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure * Pregnant or breastfeeding * Rheumatoid arthritis, Parkinson's disease or currently on dialysis * Current diagnosis of a major psychiatric condition that would impair study participation * Severe gastrointestinal disease, major gastrointestinal surgery, or active gallstone disease * Active treatment for cancer in the past year * Taking medications that preclude fasting for 16 hours (e.g. must be taken with food at least 12 hours apart)
Conditions Maturity Onset Diabetes of the Young
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Liraglutide — Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.

Primary Outcomes

  • Blood sugar control - HbA1C (Baseline and 3 months after study treatment initiation)
  • BMI (baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-08
Completion: 2027-01
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mansa
Principal Investigators:
  • Mansa Krishnamurthy, M.D. (PRINCIPAL_INVESTIGATOR) - Children's Hospital Medical Center, Cincinnati
Contact Information
Study Contact:
Mansa Krishnamurthy, M.D.
513-636-4744
mansa.krishnamurthy@cchmc.org
Lily Deng
513-636-0002
lily.deng@cchmc.org
Cincinnati Children's Hospital Medical Center
Mansa Krishnamurthy
Cincinnati Children's Hospital Medical Center
Interventions
  • Drug: Liraglutide — Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.
Study Locations (1 sites)
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of MODY via genetic testing * HgbA1c \>6.5% Exclusion Criteria: * History of anaphylaxis to GLP-1 receptor agonists * Already taking GLP-1 receptor agonists * on medications within the stimulant class * have had bariatric surgery * personal or family history of cancer, especially medullary thyroid cancer * personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis * known active kidney disease * severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment * HbA1c \> 10.0% * episode of diabetic ketoacidosis (DKA) in the past 3 months * are currently pregnant * BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile
Conditions Asthma, Chronic Rhinosinusitis With Nasa...
Phase NA
Enrollment 195
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Asthma affects the lower respiratory tract (bronchi), whereas chronic rhinosinusitis with nasal polyposis (CRSwNP) involves the upper airways. Despite this anatomical distinction, the upper and lower airways form a continuous respiratory tract and share common pathophysiological mechanisms. Consequently, asthma and CRSwNP frequently coexist, and several therapeutic strategies are effective for both conditions. Given these overlaps, we hypothesize that a multidisciplinary consultation involving both a pulmonologist and an ENT specialist could be more effective than separate consultations for patient care. We also believe that this innovative organization that would benefit the healthcare system. To test this hypothesis, we are conducting a study whose primary objective is to assess whether joint consultations lead to a reduction in oral corticosteroid need over the year following the initial consultation, by enabling more personalized treatment strategies. Secondary outcomes will include the frequency of asthma exacerbations, frequency of ENT-related events, respiratory symptoms, quality of life, and healthcare ressources utilization. We will compare outcomes between two patient groups: one receiving joint consultation from both specialists, and the other managed through standard, separate consultations as per current clinical practice.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Joint consultation — Joint consultation with pneumologist and ENT at baseline.
  • Procedure: Mucus sampling — Mucus sampling at baseline and one year follow-up
  • Procedure: Nasal brushing — Nasal brushing at baseline and one year follow-up

Primary Outcomes

  • Effectiveness of joint ENT and pulmonologist consultation on relative change in cumulative annual dose of oral corticosteroids from the year before Baseline to the year between Baseline and 12 months visit. (From the year before Baseline to the 12 months visit.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-28
Completion: 2029-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 195 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique Hopitaux De Marseille
Contact Information
Study Contact:
Laurie Pahus
+334 91 96 45 33
promotion.interne@ap-m.fr
AP-HM
Interventions
  • Other: Joint consultation — Joint consultation with pneumologist and ENT at baseline.
  • Procedure: Mucus sampling — Mucus sampling at baseline and one year follow-up
  • Procedure: Nasal brushing — Nasal brushing at baseline and one year follow-up
Study Locations (1 sites)
AP-HM, Marseille, France
Eligibility Criteria
Inclusion Criteria: * Male or female, 18 years of age or older; * With a diagnosis of asthma; * With a diagnosis of chronic rhinosinusitis with nasal polyposis; * Whose asthma and/or chronic rhinosinusitis is/are not controlled according to SNOT-22 and ACQ-6 scores; * Having used systemic corticosteroids in the previous year to treat symptoms related to one of these conditions at least; Exclusion Criteria: * Patient in a period of exclusion from another research protocol at the time of consent signature; * Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (adult patients under guardianship or curatorship, patients deprived of their liberty, pregnant or breast-feeding women); * Patients who do not read and/or understand French
Conditions Etomidate Combined With Propofol, Hypert...
Phase NA
Enrollment 166
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to access the safety of etomidate - propofol mixture vs propofol for total intravenous anesthesia in elderly patients undergoing abdominal surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: EP mixture — Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg,Cisatracurium 0.15 mg/kg,EP mixture(E:P=1:2) 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
  • Drug: Propofol — Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg,Cisatracurium 0.15 mg/kg,propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.

Primary Outcomes

  • Incidence and duration of hypotension during anesthesia (day 1 (The time from the start of anesthesia induction to extubation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2026-06-05
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 166 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tongji Hospital
Principal Investigators:
  • Shiyong Li (PRINCIPAL_INVESTIGATOR) - Department of Anesthesiology of Tongji Hospital
Contact Information
Study Contact:
Shiyong Li
02783665480
shiyongli@hust.edu.cn
Qiang Han, 02783665480
Shiyong LI
02783665480
shiyongli@hust.edu.cn
Tongji hospital
Interventions
  • Drug: EP mixture — Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg,Cisatracurium 0.15 mg/kg,EP mixture(E:P=1:2) 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
  • Drug: Propofol — Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg,Cisatracurium 0.15 mg/kg,propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
Study Locations (1 sites)
Tongji hospital, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: * ASA Ⅰ\~Ⅲ; * BMI was 18-28 kg/m2; * For elective abdominal surgery under intravenous general anesthesia; * The expected duration of anesthesia was 1 to 4 hours. Exclusion Criteria: * Septic shock and multiple organ failure diagnosed within 14 days; * Hyperkalemia (serum potassium \>5.5mmol/L) within 48 hours; * Stroke or transient ischemic attack within 3 months; * Patients with unstable angina pectoris or myocardial infarction within 3 months; Arrhythmia requiring treatment was not treated or treatment did not meet expectations; * Patients with preoperative diagnosed diabetes mellitus and uncontrolled blood glucose; Diabetic complications were diagnosed before surgery, including diabetic ketoacidosis, hyperosmolar coma, diabetes-related infection, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc. * Severe liver and renal dysfunction; * Liver surgery, renal surgery, adrenal surgery, day surgery; * Resting blood pressure ≥180/110 mmHg (2020 ISH hypertension guideline ≥ grade 3 hypertension); Or systolic blood pressure \<90mmHg or mean blood pressure \<65mmHg. * Taking corticosteroids or other immunosuppressants for more than 10 days within 6 months or having a history of adrenal cortex suppression or immune system diseases;
Conditions Breast Cancer
Phase NA
Enrollment 216
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The general objective of the study is to verify the diagnostic accuracy of contrast-enhanced mammography (CEM) compared to breast magnetic resonance imaging in patients undergoing preoperative staging for breast neoformations that have already been diagnosed and in patients undergoing neoadjuvant chemotherapy. In addition to performing a preoperative breast resonance imaging, which is always performed in these patients, one contrast-enhanced mammography per patient is planned. In patients undergoing neoadjuvant chemotherapy, which usually undergo MRI examination at the beginning, mid-cycle and at the end of chemotherapy treatment, a CEM will also be acquired same way at the beginning, mid-cycle and at the end of chemotherapy treatment. The study requires, for the execution of the contrast-enhanced mammography exam, the administration of an iodinated contrast medium that is completely analogous to that used in computed tomography.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: breast-MRI and CEM — Participants will undergo a breast MRI followed by CEM for local breast cancer staging

Primary Outcomes

  • Diagnostic accuracy of the CEDM against breast MRI (Time Frame: Up to 6 months from baseline imaging (MRI and CEDM))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-09-01
Completion: 2026-12-31
Eligibility
Age: 30 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Azienda Ospedaliera Universitaria Integrata Verona
Collaborators: GE Healthcare
Contact Information
Study Contact:
Giuseppe Cardano, MD
+390458122124
giuseppe.cardano@aovr.veneto.it
Ospedale Borgo Trento, AOUI Verona
Giuseppe Cardano, MD
Ospedale Borgo Trento, AOUI Verona
Lucia Camera, MD
Ospedale Borgo Trento, AOUI Verona
Interventions
  • Other: breast-MRI and CEM — Participants will undergo a breast MRI followed by CEM for local breast cancer staging
Study Locations (1 sites)
Ospedale Borgo Trento, AOUI Verona, Verona, Italy 37138 Italy
Eligibility Criteria
Inclusion Criteria: * women in pre-hospitalization with already established invasive breast cancer (T1-2) * over the age of 30 * with BI-RADS mammography pattern\> 1 * Written and signed informed consent for research * Negative history of adverse events to the use of iodinated and chelated contrast media of gadolinium * No significant renal impairment (EGFR\> 30 mL / min within three months before administration of the iodinated contrast medium) Exclusion Criteria: * women with breast implants * women under the age of 30 * Any contraindication to performing the MRI exam * Women with known BRCA 1 and BRCA 2 mutation
Conditions Asthma, COPD
Phase NA
Enrollment 380
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates whether adding a spacer device to triple inhaled therapy (ICS/LABA/LAMA via pMDI) can reduce acute exacerbations in elderly patients (≥65 years) with stable chronic airway diseases (COPD or asthma) who are classified as high-risk based on GOLD or GINA guidelines. High risk is defined as ≥1 hospitalization or ≥2 moderate exacerbations in the past 12 months. Despite receiving triple inhaled therapy, these patients often have poor inhaler technique due to age-related limitations. A spacer may improve drug delivery, adherence, and reduce local side effects. In this multicenter, open-label, randomized controlled trial, 380 participants will be assigned to standard therapy with or without a valved spacer. The primary outcome is the 3-month incidence of moderate-to-severe exacerbations. Secondary outcomes include lung function, adherence, inhalation technique, side effects, and patient satisfaction.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: pMDI Triple Inhaler and Spacer — Participants in this group will use a valved mouthpiece spacer in combination with standard triple inhaled therapy delivered by a pressurized metered-dose inhaler (ICS/LABA/LAMA). The spacer device helps reduce the need for hand-breath coordination, prolongs aerosol suspension time, and improves drug delivery to the lungs. Participants will be trained in proper spacer use, including device attachment, timing of actuation and inhalation, mouth seal technique, cleaning, and daily maintenance. This intervention aims to optimize inhalation technique, improve treatment adherence, and potentially reduce the incidence of moderate-to-severe exacerbations.
  • Drug: pMDI Triple Inhaler Only — Participants in the control group will receive a standard fixed-dose combination of inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA) administered via pressurized metered-dose inhaler (pMDI). No spacer will be used. All participants will receive standardized inhalation technique training at baseline, including hand-held device usage, actuation-inhalation timing, breath-hold, and mouth rinsing. This group represents the current standard-of-care for stable, high-risk COPD or asthma patients as per GOLD and GINA guidelines.

Primary Outcomes

  • Incidence of Moderate-to-Severe Acute Exacerbations Within 3 Months (Baseline, 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-17
Completion: 2027-06-30
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Ningbo University
Contact Information
Study Contact:
Chao Cao
+86-0574-87089878
caocdoctor@163.com
Shiyi He
+86-0574-87089878
shiyihii@163.com
Jing Ye
0551-63869420
plowchan@126.com
The Second Affiliated Hospital of Anhui Medical University
Interventions
  • Other: pMDI Triple Inhaler and Spacer — Participants in this group will use a valved mouthpiece spacer in combination with standard triple inhaled therapy delivered by a pressurized metered-dose inhaler (ICS/LABA/LAMA). The spacer device helps reduce the need for hand-breath coordination, prolongs aerosol suspension time, and improves drug delivery to the lungs. Participants will be trained in proper spacer use, including device attachment, timing of actuation and inhalation, mouth seal technique, cleaning, and daily maintenance. This intervention aims to optimize inhalation technique, improve treatment adherence, and potentially reduce the incidence of moderate-to-severe exacerbations.
  • Drug: pMDI Triple Inhaler Only — Participants in the control group will receive a standard fixed-dose combination of inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA) administered via pressurized metered-dose inhaler (pMDI). No spacer will be used. All participants will receive standardized inhalation technique training at baseline, including hand-held device usage, actuation-inhalation timing, breath-hold, and mouth rinsing. This group represents the current standard-of-care for stable, high-risk COPD or asthma patients as per GOLD and GINA guidelines.
Study Locations (9 sites)
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui China
The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Anhui Chest Hospital, Hefei, China
Beilun District Second People's Hospital, Ningbo, China
Ningbo Medical Center Lihuili Hospital, Ningbo, China
The First Affiliated Hospital of Ningbo University, Ningbo, China
Ninghai County First Hospital, Ninghai, China
Taizhou Central Hospital, Taizhou, China
Taizhou Municipal Hospital, Taizhou, China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥65 years, no gender restriction; 2. Confirmed diagnosis of chronic obstructive pulmonary disease (COPD) based on GOLD criteria or bronchial asthma based on GINA criteria; 3. Currently on stable treatment with fixed-dose combination ICS/LABA/LAMA via pMDI for ≥4 weeks; 4. History of any of the following in the past 12 months: 1. ≥1 hospitalization due to exacerbation, or 2. ≥2 moderate exacerbations requiring systemic corticosteroids and/or antibiotics; 5. Able to complete inhalation technique training and demonstrate basic communication and device-handling abilities; 6. Provides written informed consent to participate in the study. Exclusion Criteria: 1. Use of other inhalation devices as primary therapy (e.g., DPI, SMI, or nebulizer); 2. Regular use of a spacer device for ≥3 weeks within 3 months prior to enrollment; 3. Current or recent (within 4 weeks) acute exacerbation not fully resolved; 4. Severe cognitive impairment (MMSE score \<18); 5. Presence of severe systemic comorbidities (e.g., end-stage malignancy, advanced heart failure, hepatic or renal failure); 6. Participation in another interventional clinical trial; 7. Inability to use a mouthpiece-based spacer (e.g., structural oral/facial abnormalities, severe anxiety); 8. Known allergy or hypersensitivity to spacer device materials.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients who require a removal of a breast (mastectomy) for breast cancer or future risk reduction often have immediate breast reconstruction (IBR). This can be performed using either an implant or the patient's own body fat to recreate the breast shape. Patients can find it difficult to imagine their own post-surgery appearance. Using 3D surface imaging (3D-SI) can change a patient's pictures to show them how they might look after surgery, known as a simulation. Some patients may find 3D-SI and simulation gives them confidence in their expectations and others may not feel it helps much. This study will investigate the following 3 questions: 1. Whether 3D-SI and simulation can improve patient confidence about their likely post-surgery appearance 2. Whether 3D-SI measurement of breast shape helps in surgical planning and reduces the need for later adjustment surgery to improve symmetry, especially in patients having a mastectomy on one side only 3. How much radiotherapy changes breast reconstructions over time using 3D- SI to objectively measure this. For this study the follow up for some women who do and some who do not have radiotherapy after breast reconstruction. 3D surface imaging may improve surgeon understanding of breast shape, prior to surgery. In cases where there is a high risk of breast cancer recurrence patients are offered radiotherapy to the breast, either before or after surgery. Radiotherapy has a negative impact on the reconstructed breast, and may cause it to shrink and change position but the effect of radiotherapy has never been accurately quantified. This study will be investigating the following: 1. Whether 3D-SI measurement of breast shape helps in surgical planning and reduces the need for later adjustment surgery to improve symmetry, especially in patients having a mastectomy on one side only 2. How much radiotherapy changes breast reconstructions over time using 3D- SI to objectively measure this. For this study the follow up some women who do and some who do not have radiotherapy after breast reconstruction.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Difference in Visual Analogue Scale Score (Preioperative/Periprocedural)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-12
Completion: 2030-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal Marsden NHS Foundation Trust
Contact Information
Study Contact:
Jeane Guevara
+44 20 3186 5420
MIBREAST@rmh.nhs.uk
Astrid Leusink
Astrid.Leusink@icr.ac.uk
Royal Marsden NHS Foundation Trust
Jennifer Rusby
Royal Marsden NHS Foundation Trust
Interventions
N/A
Study Locations (1 sites)
Royal Marsden NHS Foundation Trust, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Female * Aged \> 18 * Undergoing immediate breast reconstruction (autologous or implant based) follow mastectomy for breast cancer or as a risk-reducing strategy * Available to attend 3D-SI appointments at specified intervals Exclusion Criteria: * Lack of capacity * Language barrier that prevents patients from understanding the English questionnaires * Visual impairment * Unable to answer study questionnaires * Disability that may prevent appropriate positioning during the imaging process * Unable to attend for photography * Requiring delayed reconstruction or no longer considering a reconstruction